Shares of TransMedics Group, Inc. (NASDAQ:TMDX – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $171.44.
A number of research firms recently issued reports on TMDX. Cantor Fitzgerald assumed coverage on TransMedics Group in a research note on Thursday, June 6th. They issued an “overweight” rating and a $161.00 target price on the stock. Oppenheimer upped their price objective on TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday, August 1st. Stephens lifted their price objective on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. TD Cowen upped their target price on shares of TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a report on Friday, June 7th. Finally, Piper Sandler lifted their price target on shares of TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st.
Read Our Latest Research Report on TransMedics Group
Insider Activity
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sanctuary Advisors LLC purchased a new position in shares of TransMedics Group in the 2nd quarter worth about $372,000. Teachers Retirement System of The State of Kentucky acquired a new stake in TransMedics Group during the 2nd quarter worth approximately $420,000. NewEdge Advisors LLC raised its holdings in TransMedics Group by 26.0% in the second quarter. NewEdge Advisors LLC now owns 10,372 shares of the company’s stock valued at $1,562,000 after buying an additional 2,140 shares during the period. Creative Planning raised its holdings in TransMedics Group by 78.3% in the second quarter. Creative Planning now owns 9,173 shares of the company’s stock valued at $1,382,000 after buying an additional 4,027 shares during the period. Finally, Algert Global LLC acquired a new position in TransMedics Group during the second quarter valued at approximately $2,685,000. Institutional investors and hedge funds own 99.67% of the company’s stock.
TransMedics Group Trading Down 0.6 %
Shares of TMDX stock opened at $165.00 on Friday. The stock has a market cap of $5.43 billion, a P/E ratio of -485.29 and a beta of 1.99. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. TransMedics Group has a fifty-two week low of $36.42 and a fifty-two week high of $177.37. The business has a fifty day simple moving average of $155.65 and a 200-day simple moving average of $129.31.
TransMedics Group (NASDAQ:TMDX – Get Free Report) last announced its earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The company had revenue of $114.30 million during the quarter, compared to analysts’ expectations of $98.84 million. During the same quarter in the previous year, the business posted ($0.03) earnings per share. The firm’s quarterly revenue was up 117.7% compared to the same quarter last year. On average, analysts forecast that TransMedics Group will post 1.23 earnings per share for the current fiscal year.
About TransMedics Group
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Further Reading
- Five stocks we like better than TransMedics Group
- Ride Out The Recession With These Dividend Kings
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- MarketBeat Week in Review – 9/16 – 9/20
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.